NCT01444677View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Metabolic SyndromeObesity
Interventions
DRUG

MB12066

MB12066 300mg

DRUG

MB12066

MB12066 400mg

DRUG

MB12066

MB12066 100mg

DRUG

MB12066

MB12066 200mg

DRUG

Placebo

Placebo 300mg (single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)

Trial Locations (1)

110-774

Clinical Research Institute of Seoul National University Hospital, Seoul

Sponsors

Collaborators (1)

KT&G Corporation
All Listed Sponsors
collaborator

KT&G Corporation

INDUSTRY

lead

Yungjin Pharm. Co., Ltd.

INDUSTRY

NCT01444677 - Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers | Biotech Hunter | Biotech Hunter